Show simple item record

FieldValueLanguage
dc.contributor.authorLewis, J
dc.contributor.authorLipworth, W
dc.contributor.authorDoran, E
dc.contributor.authorKerridge, I
dc.date.accessioned2016-02-15
dc.date.available2016-02-15
dc.date.issued2014-01-01
dc.identifier.citationLewis J, Lipworth W, Doran E, Kerridge I. Dilemmas in the Compassionate Supply of Investigational Cancer Drugs. Internal Medicine Journal. Published online 10 Sept 2014. 44 (2014). doi:10.1111/imj.12530en_AU
dc.identifier.urihttp://hdl.handle.net/2123/14364
dc.description.abstractIn Australia, patients who want to access medicines that are not yet approved have only two options: to enrol in a clinical trial if they are eligible, or obtain their medicine through ‘compassionate supply’, which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement. Keywords: ethics; evidence-based medicine; health services accessibility; oncologyen_AU
dc.language.isoenen_AU
dc.publisherWileyen_AU
dc.titleDilemmas in the Compassionate Supply of Investigational Cancer Drugsen_AU
dc.typeArticleen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.